SG11201810311WA - Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis - Google Patents

Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis

Info

Publication number
SG11201810311WA
SG11201810311WA SG11201810311WA SG11201810311WA SG11201810311WA SG 11201810311W A SG11201810311W A SG 11201810311WA SG 11201810311W A SG11201810311W A SG 11201810311WA SG 11201810311W A SG11201810311W A SG 11201810311WA SG 11201810311W A SG11201810311W A SG 11201810311WA
Authority
SG
Singapore
Prior art keywords
slough
berkshire
ipd
bath road
ucb
Prior art date
Application number
SG11201810311WA
Inventor
Helene Bon
Joanne Elizabeth Compson
Kate Louise Dixon
Carl Brendan Doyle
Mark Ellis
Sancho Maria Margarida Gouveia
Raymond Anthony Jupp
Lara Kevorkian
Daniel John Lightwood
Diane Marshall
Andrew Charles Payne
Joseph Michael David Rastrick
Monika-Sarah Schulze
Alison Turner
Kerry Louise Tyson
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of SG11201810311WA publication Critical patent/SG11201810311WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT omit tun Hol °Holm° Ill °nom mil (10) International Publication Number WO 2017/211873 Al (51) International Patent Classification: C07K 16/22 (2006.01) A61P 11/00 (2006.01) (21) International Application Number: PCT/EP2017/063796 (22) International Filing Date: 07 June 2017 (07.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1610044.8 08 June 2016 (08.06.2016) GB (71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Al- lee de la Recherche, 1070 Brussels (BE). (72) Inventors: BON, Helene; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). COMPSON, Joanne Elizabeth; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). DIXON, Kate Louise; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berk- shire SL1 3WE (GB). DOYLE, Carl Brendan; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). ELLIS, Mark; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). GOUVEIA SANCHO, Maria Margarida; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). JUPP, Ray- mond Anthony; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). KEVORKIAN, Lara; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). LIGHTWOOD, Daniel John; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). MARSHALL, Diane; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). PAYNE, Andrew Charles; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). RASTRICK, Joseph Michael David; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). SCHULZE, Moni- ka-Sarah; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). TURNER, Alison; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). TYSON, Kerry Louise; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). (74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Celltech, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) N co N O C (54) Title: ANTAGONIST ANTIBODIES THAT T BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS (57) : The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
SG11201810311WA 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis SG11201810311WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1610044.8A GB201610044D0 (en) 2016-06-08 2016-06-08 Antibodies
PCT/EP2017/063796 WO2017211873A1 (en) 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis

Publications (1)

Publication Number Publication Date
SG11201810311WA true SG11201810311WA (en) 2018-12-28

Family

ID=56508288

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810311WA SG11201810311WA (en) 2016-06-08 2017-06-07 Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis

Country Status (20)

Country Link
US (2) US10766956B2 (en)
EP (1) EP3468992A1 (en)
JP (1) JP2019520818A (en)
KR (1) KR20190015497A (en)
CN (1) CN109311970A (en)
AR (1) AR108779A1 (en)
AU (1) AU2017276685A1 (en)
BR (1) BR112018074869A2 (en)
CA (1) CA3024011A1 (en)
CL (1) CL2018003510A1 (en)
CO (1) CO2018012513A2 (en)
EA (1) EA201892774A1 (en)
GB (1) GB201610044D0 (en)
IL (1) IL263425A (en)
MX (1) MX2018014376A (en)
RU (1) RU2746926C2 (en)
SG (1) SG11201810311WA (en)
TW (1) TW201802115A (en)
UY (1) UY37279A (en)
WO (1) WO2017211873A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (en) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 Multispecific binding proteins for natural killer cell activation and therapeutic uses thereof for treating cancer
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
AU2019218125A1 (en) * 2018-02-08 2020-08-20 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PE20220278A1 (en) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc VARIABLE DOMAINS OF ANTIBODIES TARGETING THE NKG2D RECEPTOR
JP2022548776A (en) * 2019-09-19 2022-11-21 ノースウェスタン ユニバーシティ Cost-effective media and protocols for human induced pluripotent stem cells
KR102270700B1 (en) * 2019-11-01 2021-06-30 한국과학기술연구원 Lung-Specific Drug Delivery Consisting of Oligonucleotide Polymers and Biocompatible Cationic Peptides for the Prevention or Treatment of Pulmonary Fibrosis and Use thereof
CA3199324A1 (en) * 2020-11-17 2022-05-27 Adam Marc Silverstein Inhaled imatinib for pulmonary hypertension field
CN112961240B (en) * 2021-04-06 2022-07-05 明济生物制药（北京）有限公司 Monoclonal antibody targeting TGF-beta 1 and combined application of monoclonal antibody and mesenchymal stem cell exosome
CN112940119B (en) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 Monoclonal antibody and combined application thereof and mesenchymal stem cell exosome
WO2023147868A1 (en) * 2022-02-04 2023-08-10 Justus-Liebig-Universität Giessen Inhaled imatinib for treatment of pulmonary hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141995A1 (en) 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
RU2386638C2 (en) 2004-03-31 2010-04-20 Дженентек, Инк. Humanised anti-tgf-beta-antibody
ES2711213T3 (en) * 2005-02-08 2019-04-30 Genzyme Corp TGFbeta antibodies
AU2006330542B2 (en) 2005-12-23 2012-05-24 Eli Lilly And Company TGF-beta binding compositions
EP3254696A1 (en) * 2006-10-03 2017-12-13 Genzyme Corporation Use of tgf beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
KR102051014B1 (en) * 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Antibodies specific for tgf-beta
TWI664979B (en) 2013-03-11 2019-07-11 健臻公司 Engineered anti-tgf-beta antibodies and antigen-binding fragments
CN106794233B (en) 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 Compositions and methods relating to treatment of pulmonary hypertension
WO2017141208A1 (en) 2016-02-17 2017-08-24 Novartis Ag Tgfbeta 2 antibodies
EA201991729A1 (en) 2017-01-20 2019-12-30 Санофи ANTIBODIES TO TGF-BETA AND THEIR APPLICATION

Also Published As

Publication number Publication date
RU2018146158A (en) 2020-07-09
WO2017211873A1 (en) 2017-12-14
CN109311970A (en) 2019-02-05
GB201610044D0 (en) 2016-07-20
US20200407436A1 (en) 2020-12-31
MX2018014376A (en) 2019-03-14
AU2017276685A1 (en) 2018-11-29
AR108779A1 (en) 2018-09-26
US11518803B2 (en) 2022-12-06
US20190330321A1 (en) 2019-10-31
JP2019520818A (en) 2019-07-25
TW201802115A (en) 2018-01-16
KR20190015497A (en) 2019-02-13
EA201892774A1 (en) 2019-05-31
UY37279A (en) 2018-01-31
US10766956B2 (en) 2020-09-08
RU2746926C2 (en) 2021-04-22
IL263425A (en) 2018-12-31
EP3468992A1 (en) 2019-04-17
CO2018012513A2 (en) 2019-02-08
BR112018074869A2 (en) 2019-03-26
CA3024011A1 (en) 2017-12-14
RU2018146158A3 (en) 2020-07-09
CL2018003510A1 (en) 2019-02-01

Similar Documents

Publication Publication Date Title
SG11201810311WA (en) Antagonist antibodies that t bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808552XA (en) T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201908658TA (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
SG11201908391XA (en) Methods for modulating an immune response
SG11201806663TA (en) Closed-ended linear duplex dna for non-viral gene transfer
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201900468YA (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11201909777YA (en) Modulatory polynucleotides
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201907846VA (en) Therapeutic rna
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201901364VA (en) Engineered target specific nucleases
SG11201805805VA (en) Recombinogenic nucleic acid strands in situ
SG11201809699XA (en) Modulatory polynucleotides
SG11201809643UA (en) Compositions and methods of treating huntington's disease
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201407505XA (en) Aptamer-based multiplexed assays
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201900400QA (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123